dapsone has been researched along with Acquired Immunodeficiency Syndrome in 62 studies
Acquired Immunodeficiency Syndrome: An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the interaction between dapsone and trimethoprim in patients with the acquired immunodeficiency syndrome (AIDS)." | 9.06 | Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. ( Benowitz, NL; Jacob, P; Lee, BL; Medina, I; Mills, J; Wofsy, CB, 1989) |
| " Numerous testing modalities are performed in the ED focused on an infectious versus pulmonary etiology prior to coming to the conclusion that the source is methemoglobinemia induced by dapsone therapy." | 7.91 | Neutropenia, Hypoxia, and the Complexities of Emergency Medicine: A Case of Dapsone-Induced Methemoglobinemia. ( Blomkalns, A; Iams, A; Vu, S, 2019) |
| "The efficacy, toxicity and cost of orally administered dapsone (50-100 mg/day) for prophylaxis of Pneumocystis carinii pneumonia (PCP) were evaluated in 30 patients with AIDS or AIDS-related complex (ARC)." | 7.68 | Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. ( Deresinski, SC; Greene, SI; Kemper, CA; Kessinger, JM; Lang, OS; Stevens, DA; Tucker, RM, 1990) |
| "We have treated 113 patients with zidovudine since its licensure, 80 with acquired immunodeficiency syndrome and 33 with acquired immunodeficiency syndrome-related complex." | 7.67 | Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. ( Gor, D; Helbert, M; Janes, K; Jeffries, DJ; Kocsis, AE; Mitchell, D; Peddle, B; Pinching, AJ; Robinson, D; Stoneham, C, 1989) |
| "All patients with the acquired immunodeficiency syndrome and a first episode of Pneumocystis carinii pneumonia seen at the San Francisco General Hospital between November 1984 and April 1985 were evaluated for oral treatment with dapsone (100 mg/d) plus trimethoprim (20 mg/kg body weight X d)." | 7.67 | Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. ( Hopewell, PC; Hughes, W; Leoung, GS; Mills, J; Wofsy, C, 1986) |
| "All patients with the acquired immunodeficiency syndrome treated for their first episode of Pneumocystis carinii pneumonia at San Francisco General Hospital between 1 April 1985 and 15 July 1985 were evaluated for their response to treatment with dapsone (100 mg/day) by mouth for 21 days." | 7.67 | Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. ( Hopewell, PC; Hughes, WT; Leoung, G; Medina, I; Mills, J; Wofsy, C, 1988) |
| "In patients with AIDS, oral therapy with trimethoprim-sulfamethoxazole and with trimethoprim-dapsone are equally effective for mild-to-moderate first episodes of P." | 6.67 | Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. ( Benowitz, N; Hopewell, PC; Lee, B; Leoung, G; Medina, I; Mills, J; Modin, G; Wofsy, CB, 1990) |
| "To examine the interaction between dapsone and trimethoprim in patients with the acquired immunodeficiency syndrome (AIDS)." | 5.06 | Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. ( Benowitz, NL; Jacob, P; Lee, BL; Medina, I; Mills, J; Wofsy, CB, 1989) |
| " Numerous testing modalities are performed in the ED focused on an infectious versus pulmonary etiology prior to coming to the conclusion that the source is methemoglobinemia induced by dapsone therapy." | 3.91 | Neutropenia, Hypoxia, and the Complexities of Emergency Medicine: A Case of Dapsone-Induced Methemoglobinemia. ( Blomkalns, A; Iams, A; Vu, S, 2019) |
| "To investigate the relationship between high incidence of adverse dapsone reactions in acquired immunodeficiency syndrome (AIDS) patients and slow acetylate phenotype or low plasma/lymphocyte glutathione level of these patients." | 3.69 | Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level. ( Guo, R; Lauterberg, B; Thormann, W, 1996) |
| "The efficacy, toxicity and cost of orally administered dapsone (50-100 mg/day) for prophylaxis of Pneumocystis carinii pneumonia (PCP) were evaluated in 30 patients with AIDS or AIDS-related complex (ARC)." | 3.68 | Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. ( Deresinski, SC; Greene, SI; Kemper, CA; Kessinger, JM; Lang, OS; Stevens, DA; Tucker, RM, 1990) |
| "We have treated 113 patients with zidovudine since its licensure, 80 with acquired immunodeficiency syndrome and 33 with acquired immunodeficiency syndrome-related complex." | 3.67 | Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. ( Gor, D; Helbert, M; Janes, K; Jeffries, DJ; Kocsis, AE; Mitchell, D; Peddle, B; Pinching, AJ; Robinson, D; Stoneham, C, 1989) |
| "All patients with the acquired immunodeficiency syndrome and a first episode of Pneumocystis carinii pneumonia seen at the San Francisco General Hospital between November 1984 and April 1985 were evaluated for oral treatment with dapsone (100 mg/d) plus trimethoprim (20 mg/kg body weight X d)." | 3.67 | Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. ( Hopewell, PC; Hughes, W; Leoung, GS; Mills, J; Wofsy, C, 1986) |
| "A 44-year-old man with acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia (PCP) who suffered adverse effects from treatment with trimethoprim-sulfamethoxazole (TMP-SMX) and was then treated with pentamidine isethionate is described, and approved and investigational drugs used in the management of PCP in the AIDS patient are discussed." | 3.67 | Treatment of Pneumocystis carinii pneumonia in patients with AIDS. ( Hauptman, SP; Wordell, CJ, 1988) |
| "All patients with the acquired immunodeficiency syndrome treated for their first episode of Pneumocystis carinii pneumonia at San Francisco General Hospital between 1 April 1985 and 15 July 1985 were evaluated for their response to treatment with dapsone (100 mg/day) by mouth for 21 days." | 3.67 | Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. ( Hopewell, PC; Hughes, WT; Leoung, G; Medina, I; Mills, J; Wofsy, C, 1988) |
| "The test is applied on AIDS prophylaxis and paediatric trials." | 2.69 | Combining mortality and longitudinal measures in clinical trials. ( Finkelstein, DM; Schoenfeld, DA, 1999) |
| "The P." | 2.69 | Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. ( Armstrong, W; Burman, W; Crane, L; Hossler, PA; Katz, J; Kazanjian, P; Lee, CH; Meshnick, SR; Richardson, J, 2000) |
| "However, in AIDS patients with liver impairment and impaired glucuronidation, doses of zidovudine may need to be decreased." | 2.68 | Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. ( Gambertoglio, JG; Lee, BL; Makrides, V; Safrin, S, 1996) |
| " Six patients had received oral dapsone for at least 1 month at the dosage regimen of 100 mg twice of three times weekly and four patients had received a single oral 100 mg dose." | 2.68 | Penetration of dapsone into cerebrospinal fluid of patients with AIDS. ( Bassetti, M; Cruciani, M; Gatti, G; Hossein, J; Malena, M, 1997) |
| "In patients with AIDS, oral therapy with trimethoprim-sulfamethoxazole and with trimethoprim-dapsone are equally effective for mild-to-moderate first episodes of P." | 2.67 | Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. ( Benowitz, N; Hopewell, PC; Lee, B; Leoung, G; Medina, I; Mills, J; Modin, G; Wofsy, CB, 1990) |
| "In addition, patients with AIDS also may exhibit a defect in adrenal function, potentiating the hyperkalemic effect of TMP therapy." | 2.39 | Hyperkalemia and high-dose trimethoprim/sulfamethoxazole. ( Hsu, I; Wordell, CJ, 1995) |
| "The continuing growth of the acquired immunodeficiency syndrome (AIDS) epidemic has caused a parallel increase in patients with Pneumocystis carinii pneumonia (PCP)." | 2.38 | Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: pathophysiology, therapy, and prevention. ( Montgomery, AB, 1989) |
| "However, hypersensitivity pneumonitis from noninfectious etiologies, including environmental stimuli or drug exposure, is an unusual etiology of interstitial pneumonitis in HIV-infected patients." | 1.32 | Dapsone-induced hypersensitivity pneumonitis mimicking Pneumocystis carinii pneumonia in a patient with AIDS. ( Brown, KV; Hoteit, MA; King, MD; Ray, SM; Tobin-D'Angelo, MJ, 2004) |
| "We describe the course of 36 AIDS patients with cerebral toxoplasmosis and present a review of clinical signs, diagnosis, therapy, and survival times." | 1.31 | [HIV-associated cerebral toxoplasmosis -- review and retrospective analysis of 36 patients]. ( Evers, S; Fischer, A; Freund, M; Grüneberg, U; Happe, S; Heese, Ch; Husstedt, IW; Kloska, S; Reichelt, D, 2002) |
| "carinii prophylaxis before the onset of AIDS: Mycobacterium avium complex disease, which developed in 33." | 1.29 | Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. ( Anderson, R; Bacellar, H; Detels, R; Hoover, DR; Kaslow, RA; Phair, J; Saah, AJ, 1993) |
| "Pneumocystis carinii pneumonia has been the most common life-threatening opportunistic infection in patients with acquired immunodeficiency syndrome." | 1.29 | Dilemmas in the prophylaxis of Pneumocystis carinii pneumonia. ( Glatt, AE, 1994) |
| "The anticryptosporidial activity of four macrolides alone and in combination with other antimicrobial agents was investigated against ten clinical isolates of Cryptosporidium parvum recovered from stools of AIDS patients." | 1.29 | In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. ( Cirioni, O; Giacometti, A; Scalise, G, 1996) |
| "The prevention of the occurrence and recurrence of PCP is a cornerstone in the treatment of patients infected with the human immunodeficiency virus." | 1.28 | A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. ( Beall, GN; Beck, K; Cox, PH; Martin, MA; Styer, CM, 1992) |
| "In 33 consecutive AIDS patients with a first episode of Pneumocystis carinii pneumonia (PCP) we evaluated treatment, outcome, recurrence rate and pyrimethamine as chemoprophylaxis in a 1-year follow-up." | 1.28 | Pneumocystis carinii pneumonia in Stockholm, Sweden: treatment, outcome, one-year-follow-up and pyrimethamine prophylaxis. ( Bergdahl, S; Julander, I; Lidman, C; Lundbergh, P; Ortqvist, A, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (38.71) | 18.7374 |
| 1990's | 31 (50.00) | 18.2507 |
| 2000's | 6 (9.68) | 29.6817 |
| 2010's | 1 (1.61) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vu, S | 1 |
| Iams, A | 1 |
| Blomkalns, A | 1 |
| Happe, S | 1 |
| Fischer, A | 1 |
| Heese, Ch | 1 |
| Reichelt, D | 1 |
| Grüneberg, U | 1 |
| Freund, M | 1 |
| Kloska, S | 1 |
| Evers, S | 1 |
| Husstedt, IW | 1 |
| Calista, D | 1 |
| Tobin-D'Angelo, MJ | 1 |
| Hoteit, MA | 1 |
| Brown, KV | 1 |
| Ray, SM | 1 |
| King, MD | 1 |
| Kazanjian, PH | 1 |
| Fisk, D | 1 |
| Armstrong, W | 2 |
| Shulin, Q | 1 |
| Liwei, H | 1 |
| Ke, Z | 1 |
| Meshnick, S | 1 |
| Poulsen, A | 1 |
| Hultberg, B | 1 |
| Thomsen, K | 1 |
| Wantzin, GL | 1 |
| Hsu, I | 1 |
| Wordell, CJ | 2 |
| Salmon-Ceron, D | 1 |
| Fontbonne, A | 1 |
| Saba, J | 1 |
| May, T | 1 |
| Raffi, F | 1 |
| Chidiac, C | 1 |
| Patey, O | 1 |
| Aboulker, JP | 1 |
| Schwartz, D | 1 |
| Vildé, JL | 1 |
| Wynn, RF | 1 |
| Laing, RB | 1 |
| Leen, CL | 1 |
| Hoover, DR | 1 |
| Saah, AJ | 1 |
| Bacellar, H | 1 |
| Phair, J | 1 |
| Detels, R | 1 |
| Anderson, R | 1 |
| Kaslow, RA | 1 |
| Pertel, P | 1 |
| Hirschtick, R | 1 |
| Glatt, AE | 1 |
| Mathews, LM | 1 |
| Mathews, PJ | 1 |
| Antinori, A | 1 |
| Murri, R | 1 |
| Ammassari, A | 1 |
| De Luca, A | 1 |
| Linzalone, A | 1 |
| Cingolani, A | 1 |
| Damiano, F | 1 |
| Maiuro, G | 1 |
| Vecchiet, J | 1 |
| Scoppettuolo, G | 1 |
| Bachmeyer, C | 1 |
| Aractingi, S | 1 |
| Weinberg, GA | 1 |
| Lee, BL | 3 |
| Safrin, S | 2 |
| Makrides, V | 1 |
| Gambertoglio, JG | 1 |
| Giacometti, A | 1 |
| Cirioni, O | 1 |
| Scalise, G | 1 |
| Gatti, G | 1 |
| Hossein, J | 1 |
| Malena, M | 1 |
| Cruciani, M | 1 |
| Bassetti, M | 1 |
| Guo, R | 1 |
| Thormann, W | 1 |
| Lauterberg, B | 1 |
| Ioannidis, JP | 1 |
| Lau, J | 1 |
| Payen, MC | 1 |
| De Wit, S | 1 |
| Sommereijns, B | 1 |
| Clumeck, N | 1 |
| Finkelstein, DM | 1 |
| Schoenfeld, DA | 1 |
| Kazanjian, P | 1 |
| Hossler, PA | 1 |
| Burman, W | 1 |
| Richardson, J | 1 |
| Lee, CH | 1 |
| Crane, L | 1 |
| Katz, J | 1 |
| Meshnick, SR | 1 |
| Gordeuk, VR | 1 |
| Delanghe, JR | 1 |
| Langlois, MR | 1 |
| Boelaert, JR | 1 |
| Martin, MA | 1 |
| Cox, PH | 1 |
| Beck, K | 1 |
| Styer, CM | 1 |
| Beall, GN | 1 |
| Mohle-Boetani, J | 1 |
| Akula, SK | 1 |
| Holodniy, M | 1 |
| Katzenstein, D | 1 |
| Garcia, G | 1 |
| Hardy, WD | 2 |
| Freedberg, KA | 1 |
| Tosteson, AN | 1 |
| Cohen, CJ | 1 |
| Cotton, DJ | 1 |
| Mallolas, J | 1 |
| Zamora, L | 1 |
| Gatell, JM | 1 |
| Miró, JM | 1 |
| Soriano, E | 1 |
| Costantino, M | 1 |
| Clotet, B | 1 |
| Sirera, G | 1 |
| Romeu, J | 1 |
| Gimeno, JM | 1 |
| Jou, A | 1 |
| Condom, MJ | 1 |
| Tor, J | 1 |
| Foz, M | 1 |
| Hughes, WT | 2 |
| Kennedy, W | 1 |
| Dugdale, M | 1 |
| Land, MA | 1 |
| Stein, DS | 1 |
| Weems, JJ | 1 |
| Palte, S | 1 |
| Lancaster, D | 1 |
| Gidan-Kovnar, S | 1 |
| Morrison, RE | 1 |
| Sattler, FR | 1 |
| Young, T | 1 |
| Bill, R | 1 |
| Boylan, CT | 1 |
| Mills, J | 5 |
| Kemper, CA | 1 |
| Tucker, RM | 1 |
| Lang, OS | 1 |
| Kessinger, JM | 1 |
| Greene, SI | 1 |
| Deresinski, SC | 1 |
| Stevens, DA | 1 |
| Crosby, WH | 1 |
| Medina, I | 3 |
| Leoung, G | 2 |
| Hopewell, PC | 3 |
| Lee, B | 1 |
| Modin, G | 1 |
| Benowitz, N | 1 |
| Wofsy, CB | 2 |
| Pinching, AJ | 1 |
| Helbert, M | 1 |
| Peddle, B | 1 |
| Robinson, D | 1 |
| Janes, K | 1 |
| Gor, D | 1 |
| Jeffries, DJ | 1 |
| Stoneham, C | 1 |
| Mitchell, D | 1 |
| Kocsis, AE | 1 |
| Lucas, CR | 1 |
| Sandland, AM | 1 |
| Mijch, A | 1 |
| Simpson, JM | 1 |
| Montgomery, AB | 2 |
| Lidman, C | 1 |
| Ortqvist, A | 1 |
| Lundbergh, P | 1 |
| Julander, I | 1 |
| Bergdahl, S | 1 |
| Girard, PM | 1 |
| Gonzalez, AH | 1 |
| Berlin, OG | 1 |
| Bruckner, DA | 1 |
| Benowitz, NL | 1 |
| Jacob, P | 1 |
| McKinsey, DS | 1 |
| Durfee, D | 1 |
| Kurtin, PJ | 1 |
| Hruza, GJ | 1 |
| Friedman-Kien, AE | 1 |
| Laubenstein, LJ | 1 |
| Wernz, JC | 1 |
| Lifshitz, MS | 1 |
| Rubinstein, P | 1 |
| Leoung, GS | 1 |
| Hughes, W | 1 |
| Wofsy, C | 2 |
| Kovacs, JA | 1 |
| Masur, H | 1 |
| Fischl, MA | 1 |
| Hauptman, SP | 1 |
| Green, ST | 1 |
| Goldberg, DJ | 1 |
| Leach, J | 1 |
| Christie, PR | 1 |
| Kennedy, DH | 1 |
| Reiter, WM | 1 |
| Cimoch, PJ | 1 |
| Aubry, P | 1 |
| Oddes, B | 1 |
| Edelson, PJ | 1 |
| Metroka, CE | 1 |
| Friedman-Kien, A | 1 |
| Catterall, JR | 1 |
| Potasman, I | 1 |
| Remington, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| Phase 1 Safety Run-in Study and Phase 1b Randomized, Double Blinded, Placebo Controlled Trial[NCT05695521] | Phase 1 | 66 participants (Anticipated) | Interventional | 2023-04-03 | Recruiting | ||
| A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation[NCT01772108] | 42 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for dapsone and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Hyperkalemia and high-dose trimethoprim/sulfamethoxazole.
Topics: Acquired Immunodeficiency Syndrome; Clinical Trials as Topic; Dapsone; Drug Therapy, Combination; Hu | 1995 |
Iron status and the outcome of HIV infection: an overview.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-Infective Agents; be | 2001 |
The sulfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Hypersensitivity; Humans; Male; Opportunist | 1992 |
Prophylaxis of AIDS-related opportunistic infections (OIs). Current status and future strategies.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Animals; Cryptococcosis; Cytomegalovirus Infections; D | 1991 |
[Pneumocystis carinii pneumonia in HIV infections. Committee of the 1st Consensus Conference of anti-infectious therapy organized in May 1990 in Paris by the Société de Pathologie Infectieuse de Langue Française].
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Clinical Protocols; Dapsone; France; HIV Infections; H | 1990 |
Recent developments in the therapy and management of Pneumocystis carinii pneumonia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Drug Therapy, Combination; Humans; Pentamidine; Pneumon | 1989 |
Prophylaxis of AIDS-related opportunistic infections (OIs).
Topics: Acquired Immunodeficiency Syndrome; Cryptococcosis; Cytomegalovirus Infections; Dapsone; Drug Combin | 1989 |
Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: pathophysiology, therapy, and prevention.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Dapsone; Diet; Drug Combinations; Humans; Oxygen Inhal | 1989 |
Pneumocystis carinii pneumonia: therapy and prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Dapsone; Drug Combinations; Drug Therapy, | 1988 |
Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Antiprotozoal Agents; Clinical Trials a | 1988 |
Prevention of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Dapsone; Drug Combinations; Humans; Pentamidine; Pneum | 1988 |
15 trials available for dapsone and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aerosols; AIDS-Related Opportunistic Infections; Dapsone; | 1995 |
Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Anti-Infe | 1995 |
Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Combinations; Humans; Male; Trimethoprim; Z | 1996 |
Penetration of dapsone into cerebrospinal fluid of patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Female; Humans; Male; Middle Aged; Pneumonia, Pn | 1997 |
A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Anti-Infecti | 1997 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candi | 1999 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candi | 1999 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candi | 1999 |
Combining mortality and longitudinal measures in clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; Antifungal Agents; Candi | 1999 |
Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Dihydropteroate Synthase; Female; Humans; Male; | 2000 |
Prophylaxis of AIDS-related opportunistic infections (OIs). Current status and future strategies.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Animals; Cryptococcosis; Cytomegalovirus Infections; D | 1991 |
Low-dose co-trimoxazole, aerosolised pentamidine, or dapsone plus pyrimethamine for prevention of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Follow-Up Studies; Humans; Pentamidine; Pneumonia, Pneu | 1991 |
Prevention of Pneumocystis carinii pneumonitis in AIDS patients with weekly dapsone.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Dapsone; Drug Administration Schedule; Hum | 1990 |
Dapsone as a single agent is suboptimal therapy for Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Humans; Male; Pneumonia, Pneumocystis; Prospecti | 1991 |
Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Chemical and Drug Induced Liver Inj | 1990 |
Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions.
Topics: Acetylation; Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Interactions; Drug Therapy, Co | 1989 |
Treatment and prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Antiprotozoal Agents; Clinical Trials a | 1988 |
Pneumocystis carinii pneumonia in the patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Animals; Bronchoscopy; Clinical Trials as Topic; Dapsone; Drug C | 1985 |
38 other studies available for dapsone and Acquired Immunodeficiency Syndrome
| Article | Year |
|---|---|
Neutropenia, Hypoxia, and the Complexities of Emergency Medicine: A Case of Dapsone-Induced Methemoglobinemia.
Topics: Acquired Immunodeficiency Syndrome; Anti-Infective Agents; Dapsone; Emergency Service, Hospital; Enz | 2019 |
[HIV-associated cerebral toxoplasmosis -- review and retrospective analysis of 36 patients].
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; AIDS-Related Opportunistic Infections; Antiretrovir | 2002 |
Subcorneal pustular dermatosis in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Biopsy, Needle; Da | 2003 |
Dapsone-induced hypersensitivity pneumonitis mimicking Pneumocystis carinii pneumonia in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alveolitis, Extrinsic Allergic; Dapsone; Diagnosis, Diffe | 2004 |
Increase in prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia, in the United States and China.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Age | 2004 |
Regression of Kaposi's sarcoma in AIDS after treatment with dapsone.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Homosexuality; Humans; Male; Sarcoma, Kaposi; Sk | 1984 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
Case report of dapsone-related thrombocytosis in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Adult; Asthma; Dapsone; Humans; Male; Thrombocytosis | 1995 |
Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Candidiasis; CD4-Positive | 1993 |
Adverse reactions to dapsone in persons infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Tolerance; Humans; Male; Pneumonia, Pneumoc | 1994 |
Dilemmas in the prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Clindamycin; Dapso | 1994 |
Actionstat. Methemoglobinemia.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Emergency Nursing; Humans; Male; Methemoglobinem | 1995 |
Erythema elevatum diutinum with HIV-2 infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-Infective Agents; Dapsone; Erythema; Hand Dermatoses; HIV-2 | 1996 |
Iron overload as a mechanism for the lowered survival in AIDS patients receiving dapsone-iron protoxalate for secondary prophylaxis of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Da | 1996 |
In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Artemisin | 1996 |
Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level.
Topics: Acetylation; Acquired Immunodeficiency Syndrome; Adult; Anti-Infective Agents; Caffeine; Chromatogra | 1996 |
Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Algorithms; Anti-HIV Agen | 1998 |
A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Dapsone; Drug Administration Schedule; Drug Therapy | 1992 |
Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis.
Topics: Acquired Immunodeficiency Syndrome; Aerosols; Antiviral Agents; CD4-Positive T-Lymphocytes; Cost-Ben | 1991 |
[Some aspects of the treatment of HIV infection].
Topics: Acquired Immunodeficiency Syndrome; Clindamycin; Dapsone; HIV Infections; Humans; Primaquine; Trimet | 1991 |
Twice-weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis.
Topics: Acquired Immunodeficiency Syndrome; Brain Diseases; Dapsone; Drug Administration Schedule; Drug Ther | 1991 |
Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; AIDS-Related Complex; Costs and Cos | 1990 |
Megaloblastic pancytopenia associated with dapsone and trimethoprim treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Anemia, Macrocytic; Anemia, Megaloblastic; Dapsone; Humans; Leuc | 1990 |
Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; AIDS-Related Complex; Bone Marrow; Brain Diseases; Da | 1989 |
Primary dapsone chemoprophylaxis for Pneumocystis carinii pneumonia in immunocompromised patients infected with the human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; AIDS-Related Complex; Dapsone; Huma | 1989 |
Pneumocystis carinii pneumonia in Stockholm, Sweden: treatment, outcome, one-year-follow-up and pyrimethamine prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Dapsone; Drug Evaluation; Drug Therapy, Combination | 1989 |
[Treatment and prevention of pneumocystosis].
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Anti-Bacterial Agents; Dapsone; Humans; | 1989 |
In-vitro activity of dapsone and two potentiators against Mycobacterium avium complex.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Dapsone; Drug Synergism; Humans; Microbia | 1989 |
Megaloblastic pancytopenia associated with dapsone and trimethoprim treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Therapy, Combination; Humans; Male; Pancyto | 1989 |
Dapsone for AIDS-associated Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Humans; Male; Middle Aged; Sarcoma, Kaposi | 1985 |
Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Bronchoscopy; Dapsone; Drug Eruptions; Drug Therapy, Combination | 1986 |
Treatment of Pneumocystis carinii pneumonia.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Drug Combinations; Folic Acid Antagonists; Humans; Meth | 1987 |
Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Adult; Anti-Infective Agents; Dapsone; | 1988 |
Dapsone treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Dapsone; Drug Therapy, Combination; Humans; M | 1988 |
AIDS-related Pneumocystis carinii pneumonia successfully treated with dapsone-trimethoprim.
Topics: Acquired Immunodeficiency Syndrome; Adult; Dapsone; Drug Therapy, Combination; Humans; Male; Pneumon | 1988 |
Dapsone-induced methemoglobinemia in a patient with P. carinii pneumonia and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Humans; Male; Methemoglobinemia; Pneumonia, Pneumocysti | 1987 |
[Kaposi's sarcoma associated with AIDS].
Topics: Acquired Immunodeficiency Syndrome; Cobalt Radioisotopes; Dapsone; Humans; Interferon Type I; Sarcom | 1986 |
Dapsone, trimethoprim-sulfamethoxazole, and the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Dapsone; Drug Combinations; Humans; Pneumonia, Pneumocystis; Sul | 1985 |